Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. The company's growth is often in the single ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...